发布求助
文献互助 智能选刊 最新文献

Blood Research最新文献

筛选
英文 中文
TP53 mutation is a high-risk factor for Richter's syndrome based on circulating tumor DNA. 根据循环肿瘤DNA，TP53突变是里希特综合征的高危因素。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023189
Hee Sue Park, Bo Ra Son, Seung Myoung Son, Jihyun Kwon
{"title":"<i>TP53</i> mutation is a high-risk factor for Richter's syndrome based on circulating tumor DNA.","authors":"Hee Sue Park, Bo Ra Son, Seung Myoung Son, Jihyun Kwon","doi":"10.5045/br.2023.2023189","DOIUrl":"10.5045/br.2023.2023189","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement. 来那度胺是治疗 AL 淀粉样变性和心脏受累患者的一种方法。
IF 2.2
Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023194
Seo Yoon Jang, Ja Min Byun, Sung-Soo Yoon, Jin Chul Paeng, Seung-Pyo Lee, Youngil Koh
{"title":"Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement.","authors":"Seo Yoon Jang, Ja Min Byun, Sung-Soo Yoon, Jin Chul Paeng, Seung-Pyo Lee, Youngil Koh","doi":"10.5045/br.2023.2023194","DOIUrl":"10.5045/br.2023.2023194","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing. 临床NGS小组测试中血液系统恶性肿瘤的临床相关核心基因。
IF 2.3
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023196
Ju Sun Song
{"title":"Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing.","authors":"Ju Sun Song","doi":"10.5045/br.2023.2023196","DOIUrl":"10.5045/br.2023.2023196","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma. 伊布替尼治疗复发或难治套细胞淋巴瘤疗效的回顾性分析。
IF 2.2
Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023208
Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon
{"title":"A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.","authors":"Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon","doi":"10.5045/br.2023.2023208","DOIUrl":"10.5045/br.2023.2023208","url":null,"abstract":"<p><strong>Background: </strong>While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL (RR-MCL). This study investigated real-world treatment outcomes of ibrutinib in patients with RR-MCL.</p><p><strong>Methods: </strong>A single-center retrospective analysis investigated clinical characteristics and survival outcomes of patients with RR-MCL, treated with ibrutinib.</p><p><strong>Results: </strong>Forty-two patients were included, with 16 received rituximab and bendamustine, and 26 receiving anthracycline-based regimens as front-line treatment. During a median follow-up of 46.0 months, the response rate to ibrutinib was 69%, with 12 CRs and 8 partial responses. Disease progression (54.8%) and adverse events (11.9%) were the primary reasons for discontinuation. Median progression-free survival (PFS) and overall survival (OS) were approximately 16.4 and 50.1 months, respectively. Patients older than 70 years (<i>P</i>=0.044 and <i>P</i>=0.006), those with splenomegaly (<i>P</i>=0.022 and <i>P</i>=0.006), and those with a high-risk simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) (<i>P</i>＜0.001 and <i>P</i>＜0.001) exhibited siginificantly inferior PFS and OS. Notably, patients with a high-risk sMIPI relapsed earlier. Post-ibrutinib treatment yilded an OS of 12.2 months, while clinical trial participants demonstrated superior survival compared to those receiving chemotherapy alone.</p><p><strong>Conclusion: </strong>This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. brentuximab vedotin在复发或难治性cd30阳性淋巴瘤患者中的多中心非介入性注册:CISL1803/BRAVO研究
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023206
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
{"title":"A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.","authors":"Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang","doi":"10.5045/br.2023.2023206","DOIUrl":"10.5045/br.2023.2023206","url":null,"abstract":"<p><strong>Background: </strong>Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.</p><p><strong>Methods: </strong>This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.</p><p><strong>Results: </strong>A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (<i>P</i>=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).</p><p><strong>Conclusion: </strong>The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T-cell large granular lymphocytic leukemia with low-grade bone marrow involvement complicated by acquired pure red cell aplasia. t细胞大颗粒淋巴细胞白血病伴低级别骨髓受累并获得性纯红细胞发育不全。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023141
Bernhard Strasser, Sonja Heibl, Josef Thaler, Alexander Haushofer
{"title":"T-cell large granular lymphocytic leukemia with low-grade bone marrow involvement complicated by acquired pure red cell aplasia.","authors":"Bernhard Strasser, Sonja Heibl, Josef Thaler, Alexander Haushofer","doi":"10.5045/br.2023.2023141","DOIUrl":"10.5045/br.2023.2023141","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma-a tertiary cancer center experience. 高级别B细胞淋巴瘤的临床病理特征和治疗结果-三级癌症中心的经验。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023169
Anindya Mukherjee, Sujay Rainchwar, Aakanksha Singh, Rohan Halder, Pritish Chandra Patra, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal
{"title":"Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma-a tertiary cancer center experience.","authors":"Anindya Mukherjee, Sujay Rainchwar, Aakanksha Singh, Rohan Halder, Pritish Chandra Patra, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal","doi":"10.5045/br.2023.2023169","DOIUrl":"10.5045/br.2023.2023169","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. 自体干细胞移植后移植物功能差的多发性骨髓瘤患者应用罗米普罗stim成功恢复移植物功能差。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023185
Jeongmin Yim, Sung-Soo Park, Jong-Mi Lee, Jae-Ho Yoon, Hee-Je Kim, Chang-Ki Min
{"title":"Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation.","authors":"Jeongmin Yim, Sung-Soo Park, Jong-Mi Lee, Jae-Ho Yoon, Hee-Je Kim, Chang-Ki Min","doi":"10.5045/br.2023.2023185","DOIUrl":"10.5045/br.2023.2023185","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma. 伊鲁替尼联合吉西他滨-长春瑞滨治疗原发性难治性非霍奇金淋巴瘤。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023182
Muruvvet Seda Aydin, Esra Cengiz, Ferda Can, Simten Dagdas, Imdat Dilek, Gulsum Ozet
{"title":"Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma.","authors":"Muruvvet Seda Aydin, Esra Cengiz, Ferda Can, Simten Dagdas, Imdat Dilek, Gulsum Ozet","doi":"10.5045/br.2023.2023182","DOIUrl":"10.5045/br.2023.2023182","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in cellular immunotherapy for lymphoid malignancies. 淋巴细胞恶性肿瘤细胞免疫治疗的最新进展。
IF 2.2
Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023177
Haerim Chung, Hyunsoo Cho
{"title":"Recent advances in cellular immunotherapy for lymphoid malignancies.","authors":"Haerim Chung, Hyunsoo Cho","doi":"10.5045/br.2023.2023177","DOIUrl":"10.5045/br.2023.2023177","url":null,"abstract":"<p><p>Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in our endogenous T-cells to kill tumor cells with a focus on the basic principles of T-cell receptor recognition of major histocompatibility complex-peptide complexes. We review the factors associated with CAR T-cell outcomes and recent efforts to employ CAR T-cells in earlier lines of therapy. We also discuss the value of bispecific T-cell engagers as off-the-shelf products with better toxicity profiles. Finally, natural killer cells are discussed as an important cellular immunotherapy platform with the potential to broaden immunotherapeutic applications beyond lymphoid malignancies.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信